| ●Editorial | Yamazaki T | 178-9 |
| ●The International Meeting for Promotion of Global Clinical Development in Beppu ─What should we do for promotion? ─ | ||
| Organized by：Center for Clinical Pharmacology and Drug Development Oita University, Faculty of Medicine，The Head of the Executive Committee：Ohashi K | 181-282 | |
| ●The workshop on the issue of provisions 29th and 30th of the Declaration of Helsinki | ||
| The workshop on the issue of provisions 29th and 30th of the Declaration of Helsinki： | Lie RK | 283-310 |
| Part 1：Use of placebos in clinical trials | 285-96 | |
| Part 2：Ancillary care | 297-310 | |
| Is it possible to use placebo in clinical trials involving individuals with mental disorders （e.g. schizophrenia）? | Mitsuishi T | 311-9 |
| The randomized withdrawal study of sertraline in Japan─Was the study truly indispensable? | Saio T，Kurihara C | 321-44 |
| Provisions 29 and 30 of the Declaration of Helsinki and the ICH-E10 Guideline ─A case study of randomized placebo-controlled withdrawal trials of antidepressants and the real status of outsourcing clinical trials─ | Kurihara C，Saio T | 345-62 |
| ●Articles | ||
| A survey of the investigator's motivation to conducting clinical trials | Uno H，Takeuchi M | 363-74 |
| Current state of institutional review boards（IRB）of special functioning hospitals in Japan ─Introduction to the questionnaire survey results by The Yomiuri Shimbun and consideration for the improvement of ethical review─ | Hara S，Masuda K | 375-408 |
| ●Opinion | ||
| Problems in the marketing strategy of the subcutaneous self?injection kit for Enbrel® | Kamada I，Yokoya S | 409-14 |
| ●Forum | ||
| Microdose and William Shakespeare | Itoh K | 415-8 |
| Consideration of standards and prices of drugs in Japan | Kamada I | 419-22 |
| Comment by the editorial committee | 419 | |
| ●Instructions for authors [English] | 423-8 | |
| ●Editor's note | Takeuchi M | 429 |